Alzheimer's Drug Goes Before FDA Panel With Support

(MedPage Today) -- The controversial Alzheimer's drug candidate aducanumab received positive remarks from FDA reviewers ahead of an advisory committee meeting to be held Friday.
Aducanumab, Biogen's investigational monoclonal antibody targeting...